Welcome to our dedicated page for Predictive Oncology SEC filings (Ticker: POAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Predictive Oncology Inc. (NASDAQ: POAI), which is changing its name to Axe Compute Inc. with an expected ticker change to AGPU, provides access to the company’s official regulatory disclosures. These documents include current reports on Form 8‑K, proxy statements, and other filings that describe material events, governance decisions, financing transactions, and listing matters.
Recent Form 8‑K filings detail several key developments. One 8‑K reports the adoption of a digital asset treasury strategy supported by private placements involving cash and in‑kind contributions of ATH, the native utility token of the Aethir ecosystem. Other 8‑Ks describe the launch and terms of these private placements, related registration rights agreements, and the use of proceeds to acquire ATH and support working capital and general corporate purposes. Additional 8‑Ks cover the 1‑for‑15 reverse stock split of the company’s common stock, actions taken to address Nasdaq listing requirements, and the company’s belief that it has regained compliance with Nasdaq’s minimum stockholders’ equity requirement.
The filings also document corporate governance and shareholder matters. A definitive proxy statement on Schedule DEF 14A outlines proposals for the annual meeting, including the election of directors, ratification of the independent auditor, amendments to the 2024 Equity Incentive Plan, approval of the issuance of shares upon exercise of pre‑funded warrants, and a non‑binding advisory vote on executive compensation. Another 8‑K describes shareholder approval of these items and the resulting increase in shares available under the equity plan.
One notable 8‑K filing reports the corporate name change from Predictive Oncology Inc. to Axe Compute Inc., effective December 11, 2025, and states that the Nasdaq ticker symbol is expected to change from POAI to AGPU on or about December 12, 2025. The filing notes that outstanding stock certificates remain valid and that the CUSIP number for the common stock will not change in connection with the name change.
Through Stock Titan, users can review these SEC filings in sequence and, with AI‑powered summaries, quickly understand the implications of complex documents such as 8‑Ks, proxy statements, and registration‑related supplements. This includes identifying how financing structures, equity plans, reverse splits, and digital asset strategies affect the company’s capital structure and governance over time.
Predictive Oncology Inc. (POAI) filed a Form 3 for a director, the initial statement of beneficial ownership under Section 16. The filing states no securities are beneficially owned as of the event date 10/07/2025. The submission includes an Exhibit 24.1 Power of Attorney, and was signed by Josh Blacher, Attorney-in-Fact. This is an administrative disclosure and does not reflect a transaction.
Predictive Oncology (POAI) filed a Form 3 initial statement of beneficial ownership. The reporting person serves as Chief Investment Officer and indicated no securities are beneficially owned as of the event date 10/08/2025.
The filing includes Exhibit 24.1, a Power of Attorney, and was submitted as a single‑person filing.
Predictive Oncology set its 2025 annual meeting for November 25, 2025, in Pittsburgh at DLA Piper LLP (US). Stockholders of record on October 24, 2025 will be entitled to vote.
Stockholder proposals and proxy access requests must be received by October 26, 2025. The company expects to mail definitive proxy materials on or about November 3, 2025 and may supplement those materials, and if necessary postpone the meeting, to address any timely proposals.
Predictive Oncology Inc. filed an 8-K describing a press release issued on October 8, 2025. The release announced the closing of two private placements on October 7, 2025 and the company’s adoption of a digital asset treasury strategy, signaling a change in how it may hold part of its treasury assets. The press release is furnished under Regulation FD and attached as Exhibit 99.1, with most of its content (excluding the fifth and sixth paragraphs) also treated as an “Other Event” disclosure.
Predictive Oncology Inc. disclosed material transactions tied to private placements that include cash and cryptocurrency investments subject to customary closing conditions. The company agreed to issue placement agent warrants to purchase approximately 3.3 million shares exercisable at $0.7751 for five years and to pay a 5% cash fee to the placement agent for gross cash proceeds (excluding digital-asset proceeds). Strategic advisor warrants equal to approximately 20.3 million shares (about 7% of the securities sold) will be issued, exercisable at $0.7751 for five years and carrying a beneficial ownership cap of 4.99% (or optionally 9.99%). A Side Letter with DCI Foundation requires DCI to cure issues with locked crypto within five business days and to deliver an additional 20% of ATH tokens bought on the open market within 30 days of each purchase. The company amended bylaws effective September 26, 2025 to cap the board at seven directors. Various form agreements and exhibits were filed.
Predictive Oncology Inc. reported that it has issued a press release announcing two private placements and the adoption of a digital asset treasury strategy. The company states that it plans to maintain its existing lines of business while also pursuing this new approach to managing part of its treasury in digital assets. These updates are provided for information purposes under Regulation FD and, as described, are not being treated as filed financial information under securities law.
Predictive Oncology, Inc. filed a Form 8-K reporting a material event that includes a Certificate of Amendment to its certificate of incorporation and an attached press release dated September 25, 2025. The filing lists several numeric items (including share or schedule figures) and includes an Inline XBRL cover file. The report is signed by Josh Blacher, identified as Interim Chief Financial Officer, indicating an interim finance leader is in place. The 8-K supplies disclosure documents but does not include earnings figures, transaction details, or explanatory narrative about the amendment within the provided text.
Predictive Oncology director Nancy Chung-Welch received a grant of 64,680 restricted stock units (RSUs) on 09/09/2025. Each RSU converts to one share of common stock upon vesting and the award vests in full on October 31, 2025, subject to continued service through that date. The transaction is reported as an acquisition at a $0.00 price, leaving Ms. Chung-Welch with 83,993 shares beneficially owned after the grant.
Predictive Oncology insider grant and holdings summary
Director Daniel E. Handley was granted 64,680 restricted stock units (RSUs) on 09/09/2025. Each RSU converts to one share of common stock upon vesting, and the award is scheduled to vest in full on October 31, 2025, subject to continued service through that date. The RSUs were granted at a recorded price of $0.00. Following the grant, the reporting person beneficially owns 81,698 shares. The Form 4 indicates a single reporting person filed for this transaction.
Predictive Oncology Inc. (POAI) reported a non‑derivative grant to director Matthew Hawryluk consisting of 64,680 restricted stock units (RSUs) on 09/09/2025. Each RSU converts into one share of common stock upon vesting. The RSUs are scheduled to vest in full on October 31, 2025, contingent on continued service through that date. After the grant, Mr. Hawryluk is recorded as beneficially owning 74,168 shares of common stock. The Form 4 was signed by an attorney‑in‑fact on behalf of the reporting person on 09/11/2025.